Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Context Therapeutics Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "August 2023 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for"
03/22/2023 8-K Quarterly results
Docs: "Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates Company prioritizing pipeline to focus on CTIM-76 development and discontinuing ONA-XR program Cash runway extended into late 2024",
"March 2023 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for"
02/06/2023 8-K Quarterly results
01/27/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
01/04/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody clinical candidate",
"January 2023 Corporate Presentation Advancing Medicines for Female Cancers and Other Solid Tumors Important Notice and Disclaimers Except for"
12/08/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer"
12/01/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors CTIM-76 named as lead candidate to target Claudin 6 positive cancers IND submission expected in Q1 2024",
"Identification of CTIM-76,"
11/09/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "November 2022 Corporate Presentation Advancing Medicines for Female Cancers Important Notice and Disclaimers Except for"
09/27/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024 Company to focus resources on advancing ONA-XR ELONA Phase 1b/2 clinical trial and on advancing CLDN6xCD3 bispecific antibody toward IND",
"September 2022 Corporate Presentation Advancing Medicines for Female Cancers Forward Looking Statement Except for"
08/02/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models",
"2022 BRINGING CHANGE FOR FEMALE CANCERS"
06/03/2022 8-K Quarterly results
03/23/2022 8-K Quarterly results
01/10/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "2022 BRINGING CHANGE FOR FEMALE CANCERS"
01/05/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Context Therapeutics® Strengthens Research & Development Team",
"MASTER SERVICES AGREEMENT",
"Statement of Work No. 1 Provider Services"
12/06/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Context Therapeutics Inc. Announces Closing of $31.25 Million Private Placement"
12/02/2021 8-K Quarterly results
Docs: "Context Therapeutics® Reports Third Quarter 2021 Operating and Financial Results"
11/01/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EMPLOYMENT AGREEMENT",
"Context Therapeutics® Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Legal Officer"
10/22/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy